National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Lojuxta® is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH).

Rapid Review

Commenced Completed Outcome
09/09/2014 15/09/2014 Full Pharmacoeconomic Evaluation Recommended.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.